Cart summary

You have no items in your shopping cart.

Glycycoumarin

SKU: orb1217441

Description

Glycycoumarin is an estrogen agonist, it shows moderate inhibitory effects against CYP1A2 and CYP2B6.

Images & Validation

Key Properties

CAS Number94805-82-0
MW368.37
Purity>98% (HPLC)
FormulaC21H20O6
SMILESO=C1C(C2=CC=C(O)C=C2O)=CC3=C(OC)C(C/C=C(C)\C)=C(O)C=C3O1
TargetAutophagy
SolubilityDMSO:Soluble

Bioactivity

In Vivo
Glycycoumarin (30 μM-0.3 nM; 5 min) has an inhibitory effect on smooth muscle contraction induced by various types of stimulants through the inhibition of PDEs, especially isozyme 3, followed by the accumulation of intracellular cAMP. Glycycoumarin (10 mg/kg; i.p.; once daily for 4 d) enhances tumor growth inhibition in HepG2 xenograft model in mice and shows synergistical effect with ABT-737 (HY-50907). Animal model: Male ICR mice (aged 6 weeks, weight 25-30 g). Dosage: 30 μM-0.3 nM, 5 min. Administration:. Result: Inhibited the contraction induced by various types of stimulants, such as CCh, KCI, BaCI(2), and A23187 (calcium ionophore III). Enhanced the relaxation induced by forskolin on CCh-evoked contraction and also enhances the relaxation effect of rolipram. Associated with dose-dependent accumulation of cAMP. Animal model: HepG2 cancer cells xenograft model in male BALB/c athymic nude mice (6-7 weeks old). Dosage: 10 mg/kg. Administration: Intraperitoneal injection; once daily for 4 days; ABT-737 group was given 100 mg/kg i.p. Result: Inhibited tumor growth and resulted a reduction of the final tumor weight by 17%.
In Vitro
Glycycoumarin, (25 μM; 24 h) combining with ABT-737 (12.5 μM) synergistically, induces cell death in multiple types of liver cancer cell HepG2.Glycycoumarin is highly effective against alcoholic liver disease, nonalcoholic fatty liver disease, acetaminophen-induced hepatotoxicity, and liver cancer through mechanisms involved in activation of Nrf2 antioxidant system, stimulation of AMPK-mediated energy homeostasis, induction of autophagy degradation process, and inhibiting oncogenic kinase T-lymphokine-activated killer cell-originated protein kinase activity. Cell Viability Assay Cell line: HepG2, SMMC-7721, and Huh-7. Concentration: 10, 20, 25, 30, and 40 μM. Incubation time: 24 hours. Result: Induced cell death in multiple types of liver cancer cell lines in a dose-dependent manner.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Similar Products

  • Glycycoumarin [orb1297354]

    99.78% (May vary between batches)

    94805-82-0

    368.38

    C21H20O6

    5 mg, 10 mg, 1 mg, 25 mg, 50 mg, 100 mg, 1 ml x 10 mM (in DMSO), 200 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Glycycoumarin (orb1217441)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

100 mg
200 mg
500 mg
5 mg
$ 130.00
10 mg
$ 190.00
25 mg
$ 350.00